 | • レポートコード：MRC2103C101 • 出版社/出版日：Mordor Intelligence / 2021年2月25日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料では、世界のプロテオミクス市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品・サービス別（計装技術、試薬、ソフトウェア・サービス）分析、用途別（臨床診断、創薬、その他）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のプロテオミクス市場規模：製品・サービス別（計装技術、試薬、ソフトウェア・サービス） ・世界のプロテオミクス市場規模：用途別（臨床診断、創薬、その他） ・世界のプロテオミクス市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
Certain factors driving the market growth include rising demand for personalized medicine, increasing R&D expenditure and government funding for proteomics, and technological advancements.
These major drivers will continue to drive the biopharmaceutical industry’s pursuit of blockbuster drugs and the recent technological advances in the studies of genes and proteins. Alliances are becoming increasingly important in this field because it is challenging for companies to find all the necessary expertise to cover all activities involved in proteomics. For example, many companies working with mass spectrometry and both the manufacturers and end-user labs are collaborating with protein chip-related companies. Increased demand for personalized medicines and increased R&D in proteomics are also driving factors for the market. However, the market is constrained by strict regulatory norms and the high cost of the instruments.
Key Market Trends
Drug Discovery is Expected to Witness Healthy CAGR in Future
The identification of potential new drugs for the treatment of disease has been considered one of the most promising developments in the study of human genes and proteins. This depends on genome and proteome information for the identification of proteins, associated with a disease, which can then be used as targets for new drugs by computer software. Preclinical stages in the process of drug discovery need a multitude of genetic and biochemical assays in order to characterize the effects of drug candidates on cellular systems as well as model organisms. Almost every large pharmaceutical company now has proteomics-oriented biotech or academic partner or has started its own proteomics division. The general applications of proteomics in the drug industry include identification of efficacy and of toxicity biomarkers from readily accessible biological fluids, target identification and validation, and investigations into mechanisms of drug action or toxicity.
North America dominates the Market and expected to do Same in the Forecast Period
In North America, antibody-drug conjugates and protein therapeutics play a significant role in the treatment and diagnosis of diseases. This is a continuously evolving field with extensive research on novel and innovative next-generation therapeutics. More than a hundred modified therapeutic proteins are approved for clinical use in the region. Hundreds of protein therapeutics are in clinical trials for the treatment of cancer, immune disorders, infections, age-related diseases, and many other conditions. Besides, research on proteomics is at the highest in countries like the United States.
Competitive Landscape
The global proteomics market is highly competitive and consists of a number of major players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Inc., and Waters Corporation, among others, hold the substantial share in the proteomics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Personalized Medicine
4.2.2 Increasing R&D Expenditure and Government Funding for Proteomics
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product & Services
5.1.1 Instrumentation Technology
5.1.1.1 Spectroscopy
5.1.1.2 Chromatography
5.1.1.3 Electrophoresis
5.1.1.4 Protein Microarrays
5.1.1.5 X-Ray Crystallography
5.1.1.6 Other Instrumentation Technologies
5.1.2 Reagents
5.1.3 Software and Services
5.2 By Application
5.2.1 Clinical Diagnostics
5.2.2 Drug Discovery
5.2.3 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies, Inc.
6.1.2 Bio-Rad Laboratories, Inc.
6.1.3 Bruker Corporation
6.1.4 Danaher Corporation
6.1.5 GE Healthcare
6.1.6 Merck KGaA
6.1.7 Promega Corporation
6.1.8 Thermo Fisher Scientific, Inc.
6.1.9 Waters Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS